Detailing vs. Direct-to-Consumer Advertising in the Prescription Pharmaceutical Industry

References

• Aikin K., Swasy J., Braman A. Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs. (2004) . DTCA survey report, U.S. Food and Drug Administration, Silver Spring, MDGoogle Scholar
• Almasi E., Stafford R., Kravitz R., Mansfield P. What are the public health effects of direct-to-consumer drug advertising? PLoS Medicine (2006) 3(3):284–288Crossref, Google Scholar
• Amaldoss W., He C. Promoting prescription drugs: An experimental investigation of direct-to-consumer advertising. Marketing Sci. (2008) 28(3):472–487Link, Google Scholar
• Anand P., Sternthal B., Cafferata P., Tybout A. Strategies for designing persuasive messages: Deductions from the resource matching hypothesis. Cognitive and Affective Responses to Advertising (1989) (Lexington Books, Lexington, MA) 135–159Google Scholar
• AstraZeneca Direct-to-consumer (DTC) advertising. (2009) . http://www.astrazeneca-us.com/about-astrazeneca-us/az-on-the-issues/?itemId=4420076Google Scholar
• Bass F. M., Krishnamoorthy A., Prasad A., Sethi S. P. Generic and brand advertising strategies in a dynamic duopoly. Marketing Sci. (2005) 24(4):556–568Link, Google Scholar
• Becker G. S., Murphy K. M. A simple theory of advertising as good or bad. Quart. J. Econom. (1993) 108(4):941–964Crossref, Google Scholar
• Beecher H. The powerful placebo. J. Amer. Medical Assoc. (1955) 159(17):1602–1606Crossref, Google Scholar
• Borsook D., Becerra L. Placebo: From pain and analgesia to preferences and products. J. Marketing Res. (2005) 42(4):394–398Crossref, Google Scholar
• Boston Business Journal Sepracor's $200M Lunesta push drives sales. (2006) January 20). http://boston.bizjournals.com/boston/stories/2006/01/23/story4.htmlGoogle Scholar
• Chen Y., Joshi Y., Raju J., Zhang J. A theory of combative advertising. Marketing Sci. (2009) 28(1):1–19Link, Google Scholar
• Cramer J. The usefulness of medication compliance data in interpretation of outcomes. ISPOR News (2001) 15(October):1–4Google Scholar
• Dixit A., Norman V. Advertising and welfare. Bell J. Econom. (1978) 9(1):1–17Crossref, Google Scholar
• Friedman J. Advertising and Oligopolistic equilibrium. Bell J. Econom. (1983) 4(2):464–473Crossref, Google Scholar
• Grossman G. M., Shapiro C. Informative advertising with differentiated products. Rev. Econom. Stud. (1984) 51:63–81Crossref, Google Scholar
• Herzenstein M., Mishra S., Posavac S. How consumer's attitudes toward DTCA of prescription drugs influence ad effectiveness, and consumer and physician behavior. Marketing Lett. (2004) 15(4):201–212Crossref, Google Scholar
• Holmer A. Direct-to-consumer advertising—Strengthening our health care system. New England J. Medicine (2002) 346(7):526–528Crossref, Google Scholar
• Iizuka T., Jin G. Effect of prescription drug advertising on doctor visits. J. Econom. Management Strategy (2005) 14(3):701–727Crossref, Google Scholar
• Iizuka T., Jin G. DTCA and prescription choice. J. Indust. Econom. (2007) 55(4):771Crossref, Google Scholar
• Kohle L., Kim C.Creative Images and the Psychology of Marketing Communication (2006) (Lawrence Erlbaum Associates, Mahwah, NJ) Crossref, Google Scholar
• Loden J., Schooler C. Patient compliance. Pharmaceutical Executive (2000) 20(7):88–94Google Scholar
• Manchanda P., Wittink D., Ching A., Cleanthous P., Ding M., Dong X., Leeflang P., et al. Understanding firm, physician and consumer choice behavior in the pharmaceutical industry. Marketing Lett. (2005) 16(3/4):293–308Crossref, Google Scholar
• Marshall A.Industry and Trade: A Study of Industrial Technique and Business Organization; and of Their Influences on the Conditions of Various Classes and Nations (1921) (MacMillan, London) Google Scholar
• MedAdNews DTC takes a back seat. (2006) . http://www.pharmalive.com/magazines/medad/view.cfm?articleID=3522Google Scholar
• Narayanan S., Desiraju R., Chintagunta P. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing mix interactions. J. Marketing (2004) 68(4):90–105Crossref, Google Scholar
• Rosenthal M., Berndt E., Donohue J., Epstein A., Frank R. Demand effects of recent changes in prescription drug promotion. Frontiers Health Policy Res. (2003) 6(June):1–26Google Scholar
• Sheehan K. B. Balancing acts: An analysis of food and drug administration letters about direct-to-consumer advertising violations. J. Public Policy Marketing (2003) 22(2):159–169Crossref, Google Scholar
• Shiv B., Carmon Z., Ariely D. Placebo effects of marketing actions: Consumers may get what they pay for. J. Marketing Res. (2005) 42(November):383–393Crossref, Google Scholar
• Soberman D. A. Research note: Additional learning and implications on the role of informative advertising. Management Sci. (2004) 50(12):1744–1750Link, Google Scholar
• Sullivan S., Kreling D., Hazlet T. Non-compliance with medication regimens and subsequent hospitalization: A literature analysis and cost of hospitalization estimate. J. Res. Pharmaceutical Econom. (1990) 2(2):19–33Google Scholar
• U.S. Government Accountability Office Prescription drugs: Improvements needed in FDA's oversight of direct-to-consumer advertising. (2006) . Report, U.S. Government Accountability Office, Washington, DCGoogle Scholar
• Wosinska M. Advertising to acquire or retain. DTC Perspectives (2003) 2(3):22–26Google Scholar
• Wosinska M. Direct-to-consumer advertising and drug therapy compliance. J. Marketing Res. (2005) 42(3):323–332Crossref, Google Scholar